



Aarey

DRUGS & PHARMACEUTICALS LTD.

**MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICALS & SOLVENTS**

CIN No.: L99999MH1990PLC056538

H. O. : 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. ☎ : (022) 66312998 / 66154219 Fax : 66154219 E-mail : info@aareydrugs.com
REGD. OFF. & FACTORY : E - 34, M.I.D.C., TARAPUR, BOISAR, DIST - THANE - 401506 ☎ : (02525) 271049 E-mail : corporate@aareydrugs.com Web : www.aareydrugs.com

18th July,2016

To,
Dept. of Corporate Services
The Bombay Stock Exchange Ltd
1st floor, Rotunda Building,
M.S.Marg, Mumbai-400 001.

**Sub : UN-AUDITED QUARTERLY RESULT (CLAUSE 41) FOR THE
QUARTER ENDED 30th JUNE,2016**

Dear Sir,


Pursuant to listing agreement we are enclosing herewith the Un-audited financial results for the quarter ended 30th June,2016 with limited review report of the auditors.

Kindly acknowledge the same & oblige.

Thanking You,

Yours faithfully,

For Aarey Drugs & Pharmaceuticals Ltd


Authorised Signatory



Encl.: a/a

**Aarey****DRUGS & PHARMACEUTICALS LTD.****MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICALS & SOLVENTS**

CIN No.: L99999MH1990PLC056538

H. O. : 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. ☎ : (022) 66312998 / 66154219 Fax : 66154219 E-mail : info@aareydrugs.com
REGD. OFF. & FACTORY : E - 34, M.I.D.C., TARAPUR, BOISAR, DIST - THANE - 401506 ☎ : (02525) 271049 E-mail : corporate@aareydrugs.com Web : www.aareydrugs.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE'2016					
Sr No.	PARTICULARS	₹ In Lacs			
		QUARTER ENDED			YEAR ENDED
		30.06.2016 Unaudited	31.03.2016 Audited	30.06.2015 Unaudited	31.03.2016 Audited
1	Net Income from Sales/Services	9461.18	10863.49	4184.95	24602.87
2	Cost of Sales/Services	9202.31	10740.46	4057.59	24267.08
	a. Increase/Decrease in stock in trade & work in progress	----	----	----	----
	b. Consumption of Raw Materials	----	----	----	----
	c. Purchase of traded goods	----	----	----	----
	d. Other Expenditure	----	----	----	----
3	Gross Profit (1-2)	258.87	123.03	127.36	335.79
4	General Administrative Expenses	49.43	48.96	70.05	192.16
5	Selling and Distribution Expenses	20.25	5.46	13.88	55.42
6	Depreciation	34.73	-4.17	21.88	61.89
7	Operating Profit before Interest (3) - (4+5+6)	154.46	72.78	21.55	26.32
8	Interest	120.90	42.97	35.31	158.71
9	Exceptional Items				0
10	Operating Profit after Interest and Exceptional Items (7-8-9)	33.56	29.81	-13.76	-132.39
11	Other Income	76.55	26.12	73.85	313.69
12	Profit (+)/Loss (-) from Ordinary Activities before tax (10+11)	110.11	55.93	60.09	181.30
13	Tax Expenses	0.00	52.36	0.00	52.36
14	Net Profit (+)/Loss (-) from ordinary Activities after tax (12-13)	110.11	3.57	60.09	128.94
15	Extraordinary items (net of tax expenses)				0
16	Net Profit(+)/Loss(-) for the period(14-15)	110.11	3.57	60.09	128.94
17	Paid-up equity share capital-Rs.10/-	1681.4684	1681.4684	1681.4684	1681.4684
18	Reserves excluding revaluation reserves(as per balance sheet) of previous accounting year to be given in column (5)				1988.37
19	Earning Per Share (EPS)				
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.65	0.02	0.36	0.77
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)				
20	Public shareholding				
	-----Number of shares	7160132	7157132	7160132	7157132
	-----Percentage of Shareholding	42.58%	42.56%	42.58%	42.56%





Aarey

DRUGS & PHARMACEUTICALS LTD.

MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICALS & SOLVENTS

CIN No.: L99999MH1990PLC056538

H. O. : 107.204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. ☎ : (022) 66312998 / 66154219 Fax : 66154219 E-mail : info@aareydrugs.com
REGD. OFF. & FACTORY : E - 34, M.I.D.C., TARAPUR, BOISAR, DIST - THANE - 401506 ☎ : (02525) 271049 E-mail : corporate@aareydrugs.com Web : www.aareydrugs.com

21	Promoters and promoter group Shareholding **				
	a) Pledged/Encumbered				
	----Number of Shares	NIL	NIL	NIL	NIL
	----Percentage of Shares (as a % of the total shareholding of promoter & promoter group)				
	----Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL
	b) Non-encumbered				
	----Number of Shares	9654552	9657552	9654552	9657552
	----Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	100.00%	100.00%	100.00%	100%
	----Percentage of shares (as a % of the total share capital of the company)	57.42%	57.44%	57.42%	57.44%


Notes :-

- 1 The above financial results have been taken on record by the Board of Director's of the Company at its Board meeting held on 18.07.2016
- 2 Company has commenced commercial production on 01/06/2016
- 3 Company has started production of drug intermediate i.e. Mono Methyl Urea & Di methyl Urea, and has been accepted in the domestic market.
- 4 Company will start production of Theobromine & Theophylline API by October, 2016
- 5 Status of investors complaints (Nos) : Opening Balance as on 01.04.16 - Nil ; Received during the quarter - 3 ; Disposed off during the quarter - 3 ; Closing Balance as on 30.06.16 - Nil.

Place : Tarapur
Date : 18th July'2016

By Order of the Board of Directors
Mihir R. Ghatalia
Managing Director





The Board of Directors,

AAREY DRUGS AND PHARMACEUTICALS LIMITED,
E-34, M.I.D.C.,
TARAPUR, BOISAR
THANE-401506

Re: Limited Review of the Financial Result for the quarter ended 30th June 2016.

We have reviewed the accompanying statement of unaudited financial results of **AAREY DRUGS & PHARMACEUTICALS LIMITED** for the Quarter and period ended 30th June 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Director. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, "Review of Interim Review Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards specified under section 133 of companies Act, 2013, Read with Rule 7 of the companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DMKH & Co.
Chartered Accountants
FRN 116886W

Manish Kankani

CA. Manish Kankani
Partner
M.No. 158020
Place: Mumbai
Date: 18th July, 2016

